Antidiabetic and antimicrobial activities of fractions and compounds isolated from Berberis brevissima Jafri and Berberis parkeriana Schneid by Ali, Saqib et al.
Strathprints Institutional Repository
Ali, Saqib and Igoli, John and Clements, Carol and Semaan, Dima and Almazeb, Muhammad and
Rashid, Mamoon-Ur and Shah, Syed Qaisar and Ferro, Valerie and Gray, Alexander and Khan, M
Rafiullah (2013) Antidiabetic and antimicrobial activities of fractions and compounds isolated from
Berberis brevissima Jafri and Berberis parkeriana Schneid. Bangladesh Journal of Pharmacology,
8 (3). pp. 336-342. ISSN 1991-0088
Strathprints is designed to allow users to access the research output of the University of Strathclyde.
Copyright c© and Moral Rights for the papers on this site are retained by the individual authors
and/or other copyright owners. You may not engage in further distribution of the material for any
profitmaking activities or any commercial gain. You may freely distribute both the url (http://
strathprints.strath.ac.uk/) and the content of this paper for research or study, educational, or
not-for-profit purposes without prior permission or charge.
Any correspondence concerning this service should be sent to Strathprints administrator:
mailto:strathprints@strath.ac.uk
http://strathprints.strath.ac.uk/
 Introduction 
According to the International Diabetes Federation 
about 366 million people around the world had diabe-
tes in 2011 and the number was predicted to double by 
the year 2030 (IDF, 2013). The high risk of diabetes and 
health-related complications has led to research for 
active antidiabetic compounds from plants (Maqsood et 
al., 2009).  
Berberidaceae is a well-known family for a number of 
medicinal uses and is incorporated in the British and 
the Indian pharmacopeias (Meliani et al., 2011; British 
Pharmacopeia, 2011). Antibacterial, anticancer, anticoa-
gulant, antifatigue, antipyretic, hypoglycemic and hypo
-tensive activities have been reported for the crude 
solvent extracts and isolated compounds of various 
Berberis species (Freile et al., 2003). Root extracts of 
Berberis aristata form a bitter tonic used as a laxative and 
antiseptic (Singh et al., 2007). Some Berberis species are 
reported to have anticancer activity in human epider-
mal cells (Nicasio et al., 2011). An ethanolic extract of 
the roots of Berberis lycium has been reported to possess 
antidiabetic activity (Uniyal and Tewari, 1991). Berberis 
spp. possess berberine as a major constituent along with 
other principle isoquinoline alkaloids e.g. berbamine, 
jatrorrhizine and palmatine (Freile et al., 2003). 
Berberine, has shown significant antibacterial and anti-
fungal activities against Staphylococcus aureus and 
Candida spp (Aydemir and Biloglu, 2003). The root 
extracts of B. aristata, B. asiatica and B. lycium have also 
been reported to show good antifungal activity against 
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Abstract 
Methanol extracts of the roots of B. brevissima and B. parkeriana were examined 
for antidiabetic and antimicrobial activities. Six compounds i.e berberine, 8-
oxo-berberine, dehydrocheilanthifoline, columbamine, jatrorrhizine and gluta-
mic acid were isolated from the active fractions of these species for the first 
time. The antidiabetic activity was determined against Protein Tyrosine 
Phosphatase 1B (PTP 1B), a negative insulin regulator while the antimicrobial 
activity was performed against four bacterial strains: Mycobacterium marinum 
ATCC BAA535, sporadic Methicillin Resistant Staphylococcus aureus (SMRSA), 
endemic Methicillin Resistant Staphylococcus aureus (EMRSA) and Escherichia 
coli ATCC.8739 at different concentrations.  Amongst the isolated compounds 
8-oxo-berberine was found to be the most active antidiabetic (29 % of the 
positive control) while jatrorrhizine was the most active and selective 
antimicrobial against SMRSA and EMRSA (-1.2 % of the DMSO (D) control).  
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 Aspergillus flavus and A. terreus (WHO, 2009).  
Keeping in view the activities of the genus Berberis, we 
have selected Berberis brevissima Jafri and Berberis 
parkeriana Schneid to investigate their antidiabetic and 
antimicrobial activities. In the current study we have 
isolated six compounds and are reporting the activities 
of their fractions and the isolated compounds. 
 
Materials and Methods 
General: Compounds were isolated from fractions of 
crude extracts using Silica gel 60 (0.063-0.200 mm, 
Merck, Germany) for column chromatography (CC) 
and silica gel 60 PF254 for preparative thin layer chroma-
tography (TLC). Characterization of compounds was 
achieved using NMR instruments (Bruker AVANCE 
500 and 400 MHz, Germany) using DMSO-d6 as 
solvent. The mass spectra (EIMS) were recorded on a 
JEOL MSRoute through direct insertion probe. All the 
chemicals used were from Sigma International. 
Plant Material: Berberis brevissima Jafri and Berberis 
parkeriana roots (3 kg each) were collected from the 
north west of Pakistan, July 2009. The voucher speci-
mens (No. Bot/10701 and 8719 respectively) were depo-
sited in the herbarium of the Botany Department, 
University of Peshawar. 
Extraction and isolation: The scheme described in Figure 
1 was used for the extraction and fractionation of the 
plant material. 
Fraction A (BRA and PRA): These fractions were recrysta
-lized to give berberine (1) (2 g), mp 208-209°C (lit 208-
210°C) (Suau et al., 1998). 
Fraction C (BRC and PRC): The BRC fraction was subject
-ted to CC using silica gel (210 g) and eluted with 
CHCl3-MeOH with increasing polarity. The subfrac-
tions obtained were further subjected to preparative 
chromatography (PC) using CHCl3-MeOH-NH3 (80:20: 
0.5 and 75:25:0.5) to give 8-oxo-berberine (2) (9.1 mg) 
and dehydrocheilanthifoline (3) (7.9 mg) respectively. 
Fraction PRC was subjected to CC on silica gel (200 g) 
eluted with CHCl3-MeOH (20:80) followed by PC using 
CHCl3-MeOH-NH3 (10:90:0.5 and 75:25:0.5) to give 
columbamine (4) (11.8 mg) and dehydrocheilanthifoline 
(3) (5.3 mg). 
Fraction D (BRD and PRD): The BRD fraction (15.0 mg) 
was subjected to CC on silica gel (210 g) and eluted 
with CHCl3-MeOH with increasing polarity. The four 
fractions obtained were further separated on PC which 
afforded jatrorrhizine (5) (9.7 mg) and glutamic acid (6) 
(5.8 mg). Similarly the fraction PRD (15.0 mg) was 
subjected to CC on silica gel (210 g) and eluted with 
CHCl3-MeOH, which gave jatrorrhizine (5) (2.3 mg). 
Antidiabetic assay 
Buffer preparation: The buffer was composed of: 2.975 g 
of HEPES (H3375) (25 mM), 1.461 g of sodium chloride 
(S9625) (50 mM), 0.32 g of dithiothreitol (D5545) (2 
mM), 0.365 g of ethylene diamine tetra acetic acid 
(E1644) (EDTA, 2.5 mM) and 5 mg of bovine serum 
albumin (A2153) (BSA 0.01 mg/mL) were dissolved in 
500 mL of distilled water and the pH was adjusted to 
7.2. All chemicals were purchased from Sigma Aldrich, 
UK. 
Sample preparation: The concentration of stock solutions 
for all the samples was 10 mg/mL. Samples were screen
-ed at 100 µg/mL by taking 2 µL of each sample and 
adding it to 98 µL buffer. 
Enzyme preparation: The enzyme Protein Tyrosine 
Phosphatase 1B (PTP 1B, purchased from Invitrogen, 
Life Technologies, UK) was prepared by adding 100 µL 
to 25 mL of the buffer, then aliquoted into 250 µL lots 
(sufficient for 1 plate) which were then stored at -80°C 
until used. 
Substrate preparation: 6,8-Difluoro-4-methylumbelliferyl 
phosphate (DiFMUP) (Invitrogen D6567, Molecular 
Probes, Life Technologies, UK) was used as the 
substrate, which was dissolved in DMSO.  Seven µL of 
the stock (10 mM) was added to 1.75 mL of buffer and 
stored at -20°C until used.  
Inhibitor preparation: Bis(4-trifluoromethylsulfonamido-
phenyl)-1,4-diisopropylbenzine (TFMS, Calbiochem 
540211, 10 mg, Millipore, UK) inhibitor was dissolved 
in DMSO (10 mg in 1.64 mL) and then a displacement 
curve was drawn for the TFMS (concentration range 
0.0003-3 µM). 
Assay:  In a 96-well plate (Costar®, Sigma Aldrich, UK), 
10 µL of standard (TFMS) or samples were added to the 
plate, then 20 µL of PTP1B enzyme was added to each 
well and incubated for 30 min at 37°C in 5%CO2 in air. 
After incubation, 10 µL of the substrate was added to 
the wells followed by incubation for 10 min. The plate 
was read at 355 nm/460 nm wavelengths using Wallac 
Victor2.  
Antimicrobial assay  
The extracts and compounds were tested against 
Mycobacterium marinum ATTC.BAA535 an indicator 
species for potential activity against Mycobacterium 
tuberculosis; 2 antibiotic resistant clinical isolates of 
Staphylococcus aureus: SMRSA 106 and EMRSA 16 and 
Escherichia coli ATTC.8739. The activity of the fractions 
and compounds was assessed using a well established 
Alamar blue96TM well microplate assays. Concentra-
tions of 100, 200 and 500 µg/mL of the extracts and 
pure compounds were assessed. 
Ten mg/mL of sample was dissolved in DMSO to 
prepare the stock solution and then diluted to a 
concentration of 1 mg/mL using cation adjusted Muller 
Hinton Broth (MHB). Samples with final test concentra-
tions of 100, 200 and 500 µg/mL were prepared from 
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 the stock solutions of test samples. 
The plate was arranged with DMSO as a negative 
control in column 1, samples in columns 2-11 and a 
positive control (Gentamicin) in column 12. The micro-
bes used were diluted up to 3x104 microbes/mL.  The 
bacterial suspensions were adjusted to the same optical 
density as a 0.5 McFarland standard, then diluted 1 in 
10 for M. marinum and 1 in 100 for EMRSA, SMRSA and 
E. coli. A 100 µL suspension of the diluted microbes was 
added to all wells of the 96 well microtitre plate with 
the exception of well 1 the sterility control. Alamar blue 
was added to all wells of the MRSA, EMRSA and E. coli 
plates to give a final concentration of 10% (v/v) and a 
total well volume of 200 µL. The microplates were 
sealed with parafilm and incubated at 37°C for 24 h. 
Thereafter the levels of flouresence were detected using 
a Perkin Elmer Victor 2 microplate reader in fluores-
cence mode (excitation 560 nm, emission 590 nm). The 
Figure 1: Fractionation scheme for Berberis brevissima and Berberis parkeriana 
BR = B. brevissima roots, PR = B. parkeriana roots, BRA = B. brevissima roots fraction A, PRA = B. parkeriana roots fraction A, BRB = B. brevissima roots 
fraction B, PRB = B. parkeriana roots fraction B, BRC = B. brevissima roots fraction C, PRC = B. parkeriana roots fraction C, BRD = B. brevissima roots 
fraction D, PRD = B. parkeriana roots fraction D 
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 M. marinum plates were incubated at 31°C for 5 days 
prior to addition of Alamar blue to give a final concen-
tration of 10% (v/v). After a further 2 h incubation the 
fluorescence was determined as previously described. 
The percentage of the DMSO control values were 
recorded as % D control. 
 
Results and Discussion 
A total of six compounds were isolated for the first time 
from the different fractions of B. brevissima and B. 
parkeriana. The structures of the compounds were estab-
ished using spectroscopic techniques (UV, FT-IR, 1H 
NMR, 13C NMR, COSY, HMBC, HSQC, NOESY and 
mass spectrometry). Comparison with data reported in 
the literature confirmed the compounds to be berberine 
(1) (Hsieh et al., 2004), 8-oxo-berberine (2) (Fajardo et 
al., 1982), dehydrocheilanthifoline (3) (Cooper et al., 
1972), columbamine (4) (Hsieh et al., 2004), jatrorrhizine 
(5) (Hsieh et al., 2004) and glutamic acid (6) (Tanaka et 
al., 2007). Structures 1-6 are given in Figure 2. 
Antidiabetic activities of fractions obtained from B. 
brevissima and B. parkeriana: The fractions obtained were 
tested against PTP 1B (a negative insulin regulator).  
Samples that showed 40% of the control (i.e. 60% inhibi-
tion) were considered to be potentially active. Prelimi-
nary screening showed that fraction B (BRB = 66% and 
PRB = 59%) and D (BRD = 48% and PRD = 51%) were 
inactive against PTP 1B. The BRC fraction showed 32% 
activity of the control while PRC showed 37% of the 
control (100%). 
Antidiabetic activities of pure compounds isolated from the 
two Berberis spp.: These compounds were tested for anti-
diabetic activity against PTP 1B. Amongst the com-
pounds 8-oxo-berberine (2) was significantly active and 
showed 29% of the control. The other isolated com-
pounds i.e berberine (1) (35%), dehydrocheilanthifoline 
(3) (38%), columbamine (4) (33%) and jatrorrhizine (5) 
Figure 2: Structures of compounds 1-6 isolated from the fractions of B. brevissima and B. parkeriana  
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 (36%) also showed good activity. Glutamic acid (6) 
(78%) was inactive. 
Antimicrobial activity of B. brevissima and B. parkeriana 
fractions: The fractions of the two species were also 
tested against four microbial strains i.e M. marinum, 
MRSA, EMRSA and E. coli. Various concentrations were 
used against different strains.  The concentration tested 
against M. marinum was 100 µg/mL, SMRSA and 
EMRSA was 200 µg/mL and E. coli was 500 µg/mL. 
Fraction A consisted of mainly berberine (1), a well-
known isoquinoline alkaloid, therefore we did not test 
it against these strains. In preliminary screening, the 
fractions whose %D control was less than 5 were consi-
dered to be active. Fraction B (BRB and PRB) was not 
active against all the used strains. The BRC fraction 
showed good activity (2.4% of D control) against M. 
marinum, SMRSA (0.2% of D control) and EMRSA (0.2 
of %D control) while against E. coli it was inactive 
(45.9% of D control). The PRC fraction showed selec-
tivity as well as good activity against SMRSA (-1.1% of 
D control) and EMRSA (-1.1% of D control) while it 
showed no activity against the other two strains. The 
BRD fraction was more selective in activity and was 
only active against M. marinum (2.4% of D control). The 
PRD fraction was also active against SMRSA (1.8% of D 
control), EMRSA (-0.9% of D control) and M. marinum 
(17.6% of D control) while it was not active against E. 
coli (68.3% of D control). None of the fraction showed 
activity against E. coli (Table I). 
Antimicrobial activity of pure compounds isolated from the 
tested fractions of B. brevissima and B. parkeriana: The 
isolated compounds were also tested against the four 
strains of bacteria which were tested against the frac-
tions. Berberine (1) showed good selectivity and activity 
against SMRSA and EMRSA (1.1 and 0.5% of D control). 
The isoquinoline alkaloid, 8-oxo-berberine (2) showed 
high selectivity and good activity (1.6% of D control) 
against M. marinum and was inactive against the other 
bacterial strains. Dehydrocheilanthifoline (3), columba-
mine (4) and jatrorrhizine (5) were active against 
SMRSA (0.1, -0.6 and -1.2% of D control respectively) 
and EMRSA (-0.8, -0.9 and -1.2% of D control respec-
tively) while against M. marinum and E. coli these 
compounds were inactive. Like 8-oxo-berberine, gluta-
mic acid established good activity and high selectivity 
against M. marinum but was inactive against the other 
tested strains (Table II). 
In the past, diabetes was treated orally with medicinal 
plants or their crude extracts based on folk medicine 
(Kumar et al., 2010). More than 150 plant extracts have 
been used to treat diabetes mellitus (Eddouks et al., 2005; 
Choie et al., 1991), but there is still a need to identify 
insulin substitutes from medicinal plants. In the present 
Table I: Antimicrobial activities of fractions from B. brevissima and B. parkeriana 
  
Fractions 
M. marinum 
% of D control 
100 µg/mL 
SMRSA 
% of D control 
200 µg/mL 
EMRSA 
% of D control 
200 µg/mL 
E. coli 
% of D control 
500 µg/mL 
BRB 33.5 61.7 88.6 62.0 
BRC 2.5 0.2 0.2 45.9 
BRD 2.4 82.6 81.6 64.9 
PRB 48.0 56.0 92.3 62.9 
PRC 12.7 -1.1 -1.1 43.3 
PRD 17.6 1.8 -0.9 68.3 
BRB = B. brevissima roots fraction B, BRC = B. brevissima roots fraction C, BRD = B. brevissima roots fraction D,    
PRB = B. parkeriana roots fraction B, PRC = B. parkeriana roots fraction C, PRD = B. parkeriana roots fraction D 
Table II: Antimicrobial activities of compounds isolated from B. brevissima and B. parkeriana  
  
Compounds 
M. marinum 
% of D control 
100 µg/mL 
SMRSA 
% of D control 
200 µg/mL 
 EMRSA 
  % of D control 
 200 µg/mL 
E. coli 
% of D control 
500 µg/mL 
Berberine (1) 47.4 1.1  0.5 57.8 
8-Oxo-berberine (2) 1.6 18.9  32.6 56.3 
Dehydrocheilanthifoline (3) 26.4 0.1  -0.8 44.1 
Columbamine (4) 45.9 -0.6  -0.9 51.7 
Jatrorrhizine (5) 18.8 -1.2  -1.2 39.4 
Glutamic acid (6) 0.9 35.7  47.8 49.3 
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 study, the effect of various fractions (BRB, BRC, BRD, 
PRB, PRC and PRD) and their isolated compounds 
were examined against PTP 1B. The antidiabetic study 
showed that fraction C (BRC and PRC) is very active 
against PTP 1B. Fraction C (BRC and PRC) and D (BRD 
and PRD) were further analyzed to isolate active 
constituents. Out of the six isolated compounds, 8-oxo-
berberine (2) showed good activity against PTP 1B. 
Other isolated alkaloids were also good in activity since 
the literature has shown that many alkaloids have 
antidiabetic activities (Maqsood et al., 2009), while gluta
-mic acid (6) was inactive. 
The crude methanolic extract of B. aristata DC, has 
shown significant hypoglycemic activity in streptozo-
tocin-induced diabetic rats (Upwar et al., 2011). 
Animals treated with a Berberis root extract and 
berberine have also shown considerable decrease in 
blood glucose levels as well as glycosylated hemoglobin 
levels in diabetic animals (Gulfraz et al., 2008). 
Berberine enhances the intracellular calcium which 
increases degranulation and release of insulin from β-
cells (Xu et al., 1997). 
A major therapeutic intervention in modern medicine, 
used in surgery, chemotherapy and other diseases, 
involves antibiotics (Brag et al., 2005). However resis-
tance to antibiotics of many harmful bacteria is develop
-ing daily (Schito et al., 2006). The need for better drugs 
to combat the problem of resistance can not be over 
emphasized (Wagh and Vidhale, 2010). In the present 
study, we have tested B. brevissima and B. parkeriana 
fractions and the six isolated compounds against four 
strains of bacteria. Among the tested fractions; fraction 
C (BRC and PRC) and D (BRD and PRD) showed good 
activity against three strains while all of the fractions 
were inactive against E. coli ATTC.8739. The two frac-
tions were further studied for their active constituents 
responsible for their antimicrobial activity. The isolated 
compounds showed good selectivity and activity 
against three bacterial strains while they were all 
inactive against E. coli.     
A literature survey showed that although Berberis 
species are medicinally important, their antibacterial 
activities are limited (Dutta and Panse, 1962). B. aristata 
extracts have significant antibacterial and antifungal 
potential against clinical and other reference strains 
(Shahid et al., 2009), while the isoquinoline alkaloids 
have significant in vitro antimicrobial activities (Zhang 
et al., 2012).  
In conclusion, the present study suggests that B. 
brevissima and B. parkeriana have potential activity for 
treating diabetes and could be useful against some 
antibiotic resistant microbes. This provides some 
guidance towards further in vitro and in vivo testing of 
compounds to further assess their antidiabetic and 
antimicrobial properties. 
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